Adaptive Biotechnologies sees stock surge after clonoSEQ EU certification
In a major development for the biotechnology sector, Adaptive Biotechnologies Corporation witnessed a remarkable 29% surge in its stock value following a key regulatory milestone. ... Read More
MaaT Pharma commences HERACLES Phase 2 trial for MaaT013 in battle against acute graft-versus-host disease
MaaT Pharma, a French oncology company, has announced a significant milestone in its clinical research: the dosing of the first patient in the HERACLES Phase ... Read More